KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CareDx (CDNA) Research & Development (2016 - 2025)

CareDx's Research & Development history spans 13 years, with the latest figure at $19.3 million for Q4 2025.

  • For Q4 2025, Research & Development rose 16.16% year-over-year to $19.3 million; the TTM value through Dec 2025 reached $71.4 million, down 1.49%, while the annual FY2025 figure was $71.4 million, 1.49% down from the prior year.
  • Research & Development for Q4 2025 was $19.3 million at CareDx, up from $16.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $24.4 million in Q1 2023 and bottomed at $16.0 million in Q1 2021.
  • The 5-year median for Research & Development is $19.2 million (2021), against an average of $19.7 million.
  • The largest annual shift saw Research & Development soared 65.45% in 2021 before it fell 23.18% in 2024.
  • A 5-year view of Research & Development shows it stood at $22.0 million in 2021, then rose by 6.91% to $23.6 million in 2022, then dropped by 20.11% to $18.8 million in 2023, then dropped by 11.74% to $16.6 million in 2024, then rose by 16.16% to $19.3 million in 2025.
  • Per Business Quant, the three most recent readings for CDNA's Research & Development are $19.3 million (Q4 2025), $16.8 million (Q3 2025), and $16.8 million (Q2 2025).